Work

Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8576

Authors: Shaji Kumar, Ravi Vij, Jonathan L. Kaufman, Joseph Mikhael, Thierry Facon, Philippe Moreau, Martine Amiot, Stefanie Alzate, Lura J Morris, Jeremy A Ross, Martin Dunbar, Ming Zhu, Suresh K Agarwal, Joel Leverson, Sari H. Enschede, Rod Humerickhouse, Cyrille Touzeau

Institutions: Mayo Clinic, Washington University in St. Louis, Emory University, Mayo Clinic in Arizona, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Nantes, AbbVie (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596920682

Cites:

Cited by: 7

Related to: 10